Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.

Rigel ( (RIGL)) has issued an update. On February 1, 2026, Rigel Pharmaceuticals appointed Michael P. Miller to its board of directors, where he will serve in the director class whose term runs until ...

Texas Instruments on Wednesday agreed to buy Silicon Laboratories ⁠in a deal valuing the chip designer at $7.5 billion, to expand its footprint in wireless connectivity chips used for industrial and ...

Feb 4 (Reuters) - Texas Instruments (TXN.O), opens new tab on Wednesday agreed to buy chip designer Silicon Laboratories (SLAB.O), opens new tab for about $7.5 billion, aiming to expand its presence ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Texas Instruments has agreed a deal to buy chip designer Silicon Laboratories for $7.5bn as a wave of ...

Feb 4 (Reuters) - Texas Instruments on Wednesday agreed to buy chip designer Silicon Laboratories for about $7.5 billion, aiming to expand its presence in wireless connectivity chips used in ...

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has ...